Hair Multiplication: RepliCel Life Sciences Inc. Provides Update on First Human Study

In an attempt to become the first biotechnology company to offer a reliable [tag]hair multiplication[/tag] therapy, [tag]RepliCel[/tag] Life Sciences Inc. recently released an update on its first human clinical research trial.

During the trial, 19 individuals (10 male and 9 female [tag]hair loss[/tag] sufferers) were treated with a series of [tag]Replicel hair multiplication[/tag] and placebo injections in various regions of the scalp.

To assess the success of the hair multiplication injections, the researchers will analyze all injected areas of the scalp at maturation and note where new [tag]hair growth[/tag] is seen.  If a greater amount of new growth is observed in the hair multiplication injection sites (compared to the placebo injection sites), then the product may have some merit in actually generating new hair.

During the recent 6 month update, Replicel evaluated the health and well-being of 17 of the 19 study participants and determined all patients were healthy and aren’t experiencing adverse effects from the treatment. Because of this, Replicel is on track to review the actual efficacy of the treatments in April 2012 and release final results in late 2013.

Check back for future RepliCel updates. To review the official press release, click here.
_______________
Blake  – aka Future_HT_Doc

Editorial Assistant and Forum Co-Moderator for the Hair Transplant Network, the Hair Loss Learning Center, the Hair Loss Q&A Blog, and the Hair Restoration Forum

Follow our community on Twitter

Watch hair transplant videos on YouTube